The invention relates to a method for the production of milk with a high content of native vitamin D3, comprising the irradiation of one or more lactating animals in a roofed enclosure, having at least one luminaire with a lamp emitting UV-A and UV-B radiation, and the milking of animals. The method allows producing milk having a high content of native vitamin D. The method also leads to an improved milk yield per animal.

The present invention relates to a device for applying energy to a human body. The device comprises a contact surface which defines an application region in which a human body can be placed in the effective range of the energy. The device further comprises at least one means for outputting the energy directed substantially onto the application region, and at least one means for generating a vapour mixture comprising at least one cannabinoid. The device according to the invention also comprises at least one means for guiding the vapour mixture, which has an effective dose of at least one cannabinoid, into the surroundings of the breathing orifices of a human body. The present invention further relates to a method for operating such a device, and to the use of vapour mixtures comprising at least one cannabinoid in designated devices.

Photobiomodulation therapy systems provide a highly effective way to treat many common ailments to the human body. Many embodiments described herein enable two or more light therapy devices to be communicatively coupled together in various ways. In some embodiments, the light therapy system includes a first light device and a second light device arranged and configured to be communicatively coupled to the first light device. Each of the light devices may include a housing, a communication module, and a plurality of lights arranged and configured to emit at least one of red light and near infrared light.

Photobiomodulation therapy systems provide a highly effective way to treat many common ailments to the human body. Many embodiments described herein enable two or more light therapy devices to be communicatively coupled together in various ways. In some embodiments, the light therapy system includes a first light device and a second light device arranged and configured to be communicatively coupled to the first light device. Each of the light devices may include a housing, a communication module, and a plurality of lights arranged and configured to emit at least one of red light and near infrared light.

A device includes light sources, electromagnetic field generators, and vibration components to apply a variety of treatment regimens to a living animal organism, including a human person or a body part of a person. The light and electromagnetic therapy are applied at frequencies which have physiological effects, and which can be combined to induce lipolysis, stimulate muscle, and achieve other effects. Feedback is used to dynamically adjust the intensity, duration, and other parameters of the light, electromagnetic, and vibration treatment modalities.

A light therapy device mounting system may include an elongate pole comprising a plurality of holes, a first end and a second end, a mounting device slideably coupled to the elongate pole via at least one hole of the plurality of holes, a top bracket slideably coupled to the first end of the elongate pole, and a bottom bracket slideably coupled to the second end of the elongate pole. The top bracket may include a top hook for receiving a top portion of a door, and the bottom bracket may include a bottom hook for receiving a bottom portion of the door.

A chamber providing controlled amounts of IR and visible light within an internal space sized to seat at least one human being. The chamber includes at least one heater configured to emit FIR energy, at least one heater configured to emit NIR energy, and at least one heater configured to emit at least MIR energy. The chamber includes at least one light emitting source configured to emit a selected wavelength of visible light, and a control panel configured to control the amount and duration of FIR, MIR, NIR and visible light within the chamber.

Photobiomodulation therapy systems provide a highly effective way to treat many common ailments to the human body. Many embodiments described herein enable two or more light therapy devices to be communicatively coupled together in various ways. In some embodiments, the light therapy system includes a first light device and a second light device arranged and configured to be communicatively coupled to the first light device. Each of the light devices may include a housing, a communication module, and a plurality of lights arranged and configured to emit at least one of red light and near infrared light.

Dynamic dosing systems for phototherapy and associated devices, systems, and methods are disclosed herein. In some embodiments, a dynamic dosing phototherapy system can include a self-service phototherapy kiosk (“SPK”) configured to emit UV radiation, a user interface communicatively coupled to the SPK, and a dynamic dosing system communicatively coupled to the user interface and the SPK. The dynamic dosing system can determine initial, user-specific parameters specific to define a first individual phototherapy protocol, and then determine adjustments to the initial parameters and the first individual phototherapy protocol based on user inputs related to erythema response to a previous phototherapy treatment session. The SPK can deliver UV radiation to a user in accordance with the first individual phototherapy protocol and/or an adjusted, second phototherapy protocol that takes into account the user's erythema response.

A therapy, treatment and process for inactivating and/or killing COVID-19 (Corona Virus Disease 2019) is provided, including a low-dose, full body, Ultraviolet A1 (UV-A1, 360-400 nm) photon therapy, wherein the UV-A1 photon therapy activates singlet oxygen (.sup.1O.sub.2), which inactivates and/or kills COVID-19. UV-A1 therapy of the present invention can also be used to help alleviate symptoms and secondary illnesses caused by COVID-19. UV-A1 therapy of the present invention can also be used to help alleviate and treat pre-existing conditions of people that are also suffering from COVID-19 and worsened by COVID-19.